Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31858 Phase II in Bronchial Asthma
NCT06637254Phase 2Enrolling by invitation
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HSK31858 in asthma, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Annualized asthma exacerbation rate within 24 weeks. Started Oct 2024; status: enrolling by invitation.
02
Drugs
HSK31858
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06637254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637254.